As the global economy mends, the 2021 growth of Respiratory Syncytial Virus Vaccines will have significant change from previous year. According to our (LP Information) latest study, the global Respiratory Syncytial Virus Vaccines market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Respiratory Syncytial Virus Vaccines market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028. The United States Respiratory Syncytial Virus Vaccines market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Respiratory Syncytial Virus Vaccines market, reaching US$ million by the year 2028. As for the Europe Respiratory Syncytial Virus Vaccines landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period. Global main Respiratory Syncytial Virus Vaccines players cover Pfizer Inc.Pfizer Inc., Sanofi, Merck Sharp & Dohme, and GlaxoSmithKline, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021. This report presents a comprehensive overview, market shares, and growth opportunities of Respiratory Syncytial Virus Vaccines market by product type, application, key players and key regions and countries. Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7. Palivizumab RSVpreF PF06928316 RSVPreF3 OA (GSK3844766A) mRNA-1345 Janssen RSV Vaccine ResVax Nirsevimab (MEDI8897) MVA-BN RSV Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8. Hospital Clinic Research Institute This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8. Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3. Pfizer Inc.Pfizer Inc. Sanofi Merck Sharp & Dohme GlaxoSmithKline SOBI Johnson & Johnson Bavarian Nordic Novavax AstraZeneca Moderna Codagenix Intravacc Alphavax
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Respiratory Syncytial Virus Vaccines Market Size 2017-2028 2.1.2 Respiratory Syncytia
